Literature DB >> 15877737

The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system.

Hong Chang1, Eric S Bartlett, Bruce Patterson, Chris I Chen, Qi Long Yi.   

Abstract

By immunohistochemistry, the CD56-positive myeloma cells were detected in three (38%) bone marrow (BM) and one (13%) cerebrospinal fluid (CSF) samples from eight patients with multiple myeloma involving the central nervous system (CNS MM). Of the three patients with CD56-positive BM myeloma cells, two had CSF myeloma cells negative for CD56. In a control cohort of 84 MM patients without CNS involvement, the BM myeloma cells were CD56-positive in 68 (80%) cases (P < 0.0001). The prevalence of CD56-negative myeloma cells in the BM and CSF of our patients suggests that CD56 downregulation may play a role in the pathogenesis of CNS MM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877737     DOI: 10.1111/j.1365-2141.2005.05493.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Neural cell adhesion molecule isoform 140 declines with rise of WHO grade in human gliomas and serves as indicator for the invasion zone of multiform glioblastomas and brain metastases.

Authors:  Pedro Duenisch; Rupert Reichart; Ulrike Mueller; Michael Brodhun; Rolf Bjerkvig; Bernd Romeike; Jan Walter; Christian Herbold; Christian R A Regenbrecht; Rolf Kalff; Susanne A Kuhn
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-04       Impact factor: 4.553

Review 2.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

Review 3.  Multiple myeloma with t(11;14): unique biology and evolving landscape.

Authors:  Susan Bal; Shaji K Kumar; Rafael Fonseca; Francesca Gay; Vania Tm Hungria; Ahmet Dogan; Luciano J Costa
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 4.  Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.

Authors:  Johann Micallef; Moyez Dharsee; Jian Chen; Suzanne Ackloo; Ken Evans; Luqui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2010-04-07       Impact factor: 17.388

5.  Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.

Authors:  Laura Todaro; Silvia Christiansen; Mirta Varela; Paola Campodónico; M Guadalupe Pallotta; José Lastiri; Eugenia Sacerdote de Lustig; Elisa Bal de Kier Joffé; Lydia Puricelli
Journal:  J Neurooncol       Date:  2007-01-10       Impact factor: 4.506

Review 6.  CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?

Authors:  Yanquan Liu; Jianzhen Shen; M Awal Issah; Tingbo Liu; Huarong Zhou; Haiying Fu
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

7.  Intracranial Involvement in Multiple Myeloma Presenting as a Cranial Nerve Palsy.

Authors:  Eilis Fitzgerald; Patrick Kiely; Hilary O Leary
Journal:  J Hematol (Brossard)       Date:  2019-03-30

8.  Hepatic manifestations in hematological disorders.

Authors:  Jun Murakami; Yukihiro Shimizu
Journal:  Int J Hepatol       Date:  2013-03-31

Review 9.  Multiple myeloma with central nervous system relapse.

Authors:  Philip A Egan; Patrick T Elder; W Ian Deighan; Sheila J M O'Connor; H Denis Alexander
Journal:  Haematologica       Date:  2020-05-15       Impact factor: 9.941

10.  Isolated central nervous system relapse of multiple myeloma post autologous stem cell transplant- A rare presentation.

Authors:  Abhenil Mittal; Deepam Pushpam; Lalit Kumar
Journal:  Leuk Res Rep       Date:  2020-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.